What 7 Analyst Ratings Have To Say About Celldex Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 7 analysts have published their opinion on Celldex Therapeutics (NASDAQ:CLDX) stock. The company has an average price target of $48.86, a decrease of 23.06% from the previous average price target of $63.50. The ratings include 1 bullish, 4 somewhat bullish, 1 indifferent, and 1 somewhat bearish.
November 10, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analysts have given mixed ratings to Celldex Therapeutics, with an average price target of $48.86, down 23.06% from the previous target. This could indicate uncertainty about the company's future performance.
The mixed ratings from analysts indicate a lack of consensus about the future performance of Celldex Therapeutics. The decrease in the average price target could suggest that analysts are less optimistic about the company's prospects than they were previously. This could potentially impact the stock's performance in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100